Anti-Amyloid Beta Antibody (DLX212) represents a highly specialized humanized monoclonal antibody specifically engineered to target various forms of Amyloid Beta (Aβ) with exceptional binding affinity. It effectively facilitates the measurable clearance of amyloid plaques across various preclinical experimental models to evaluate the reduction of neurotoxicity and the restoration of synaptic plasticity during strictly monitored laboratory observation periods and functional cognitive assays.